Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD, Madrid, Spain)
IIS-FJD is a biomedical research institute partnership between the Fundacion Jimenez Diaz Hospital and the Universidad Autonoma de Madrid, one of the highest ranked Spanish universities. Since 1980 the Nephrology Department has strong expertise in clinical and experimental CKD. Its researchers have unravelled the human diabetic nephropathy kidney transcriptome with identification and characterisation of novel mediators of kidney and vascular injury and description of their interactions in cell culture and animal models. There is vast research expertise in molecular mechanisms involved in cell death and proliferation, inflammation and fibrosis, as well as in animal models of kidney disease.
Prof. Dr. Alberto Ortiz, Department of Nephrology: https://www.era-edta.org/Ortiz2012.html
EUTox work group (Europe)
EUTox is a working group of the "European Society of Artificial Organs" (ESAO) and an endorsed working group of the "European Renal Association-European Dialysis Transplantation Association" (ERA-EDTA). The EUTox working group is composed of twenty six academic and seven industrial members. The topic of the EUTox working group is the identification of yet unknown uremic toxins contributing to CKD and associated increased cardiovascular risk, the characterization of uremic toxins and the development of new therapeutic approaches for the treatment of CKD and associated vascular pathology.
Prof. Dr. Danilo Fliser, Department of Nephrology, Saarland University,
Campus Homburg, Germany: https://www.era-edta.org/Fliser2015.html
Catholic University Leuven (Leuven, Belgium)
Founded in 1425, the Catholic University of Leuven bears the double honour of being the oldest existent catholic university in the world and the oldest university in the Low Countries. The laboratory of Nephrology belongs to the Department of Microbiology and Immunology within the Catholic University of Leuven, Belgium, and is specialized in kidney transplantation and dialysis of CKD patients.
Prof. Dr. Pieter Evenepoel (Department of Nephrology): https://www.kuleuven.be/wieiswie/en/person/00034199
Bayer Pharma AG (Wuppertal, Germany)
Bayer Pharmaceuticals Division markets pharmaceutical products in >100 countries. More than 60,700 members of staff currently work for Bayer Pharmaceuticals worldwide – more than 8,100 in research and development alone. Pharmaceutical drug discovery research and development at Bayer is concentrated on Cardiology & Hematology among other R&D areas like Oncology.
Dr. Axel Kretschmer, Pharmaceuticals Division, Wuppertal: https://www.researchgate.net/profile/Axel_Kretschmer
Fresenius Medical Care (Hessen, Germany)
Fresenius Medical Care is the world's leading provider of products and services for people with chronic kidney failure. They care for more than 300.000 patients in their global network of more than 3.500 dialysis clinic, and operate ~40 production sites on all continents to provide dialysis products such as dialysis machines, dialyzers and related disposables. They aim to continuously improve the quality of life of patients with kidney disease by offering innovative products and treatment concepts of the highest quality.
Dr. Sonja Steppan, Director Biomedical Research, Center of Excellence Medical: https://www.linkedin.com/in/sonja-steppan-5b26221/
Exelixis Research Management (Athens, Greece)
Exelixis is an SME based in Athens, Greece. It provides consultancy and a wide range of management services in the field of Research and Technological Development. In CaReSyAn, Exelixis will assist the coordinator in all management aspects and also will be actively involved in the dissemination/communication activities.
Ms Dora Togia, Administrative Manager - email@example.com
RD - Néphrologie (Montpellier, France)
RD – NEPHROLOGIE is a SME founded by Dr Àngel Argilés, former research director at the CNRS, with expertise in research and development in the context of renal pathology. RD – NEPHROLOGIE markets its R&D services to pharmaceutical industries developing new products as well as an expertise in clinical research, evaluation of therapeutic innovations and fundamental biology, in the context of projects co-developed with pharmaceutical industries and research laboratories.
Dr Angel Argilés, President. http://www.rd-n.org/?page_id=5291&lang=en